Floatz logo

Eloxatin

Gastric or Gastroesophageal Junction Adenocarcinoma

Memorial Sloan Kettering Cancer CenterPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Gastric or Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Diwakar Davar
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B
Capecitabine
Shanghai Zhongshan Hospital
Phase 3B

View all 50 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →